Brief by Shorts91 Newsdesk / 08:01am on 08 Sep 2025,Monday Health & Wellness
Russia's Enteromix cancer vaccine has achieved 100% efficacy and safety in early clinical trials targeting colorectal cancer. Developed using mRNA technology similar to COVID-19 vaccines, the personalized immunotherapy is tailored to each patient's tumor profile. The trial involved 48 volunteers and was conducted by Russia's National Medical Research Radiological Centre with the Engelhardt Institute of Molecular Biology. Patients experienced tumor shrinkage without serious side effects. Announced at the 2025 St. Petersburg International Economic Forum, the vaccine awaits regulatory approval from Russia's Ministry of Health. Unlike conventional cancer vaccines, Enteromix offers fully personalized design and rapid mRNA platform adaptability, potentially transforming cancer treatment globally if validated through larger trials. (PC: X)
